Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 9/20 | 0.67 |
| ▸ | RAB9A | P51151 | 9/20 | 0.67 |
| ▸ | MEN1 | O00255 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.67 |
| ▸ | RELA | Q04206 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6227837 | 0.94 | GAA (0.68) | GAACYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL4909101 | 0.93 | NPC1 (0.70) | GAACYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL1148016 | 0.90 | GAA (0.64) | GAACYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL6072751 | 0.86 | ALDH1A1 (0.60) | GAACYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL27311843 | 0.85 | GAA (0.57) | GAACYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL27453604 | 0.85 | ADORA1 (0.61) | GAACYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL27452891 | 0.85 | ADORA1 (0.61) | GAACYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL27453600 | 0.85 | ADORA1 (0.61) | GAACYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL27453596 | 0.85 | ADORA1 (0.61) | GAACYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL27453599 | 0.85 | ADORA1 (0.61) | GAACYP1A2CYP2C19NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | 1ST Biotherapeutics, Inc. (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | 1ST Biotherapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| US-20130289022-A1 | TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2013-10-31 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1802303-B1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INHIBITING A-SYNUCLEIN TOXICITY | WHITEHEAD BIOMEDICAL INST (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| US-3761490-A | CYCLOPROPANE-CARBOXYLIC ACID BENZOTHIAZYLAMIDES | BAYER AG | 1973-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | GAA 62/4885CYP1A2 2530/4885CYP2C19 2282/4885 |
| US-11649255-B2 | Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same | IP6K1, HIPK1, IP6K3 | GAA 1829/4885CYP1A2 1840/4885CYP2C19 1320/4885 |
| US-20220098193-A1 | INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME | IP6K1, HIPK1, IP6K3 | GAA 1829/4885CYP1A2 1840/4885CYP2C19 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.